Peta V

Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

Peta V et al. · World J Hepatol · 2025

ActiTest FibroTest AIH

Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Poynard T et al. · Diagnostics (Basel) · 2025

FibroTest-T2D Metabolic

Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.

Poynard T et al. · Hepatol Commun · 2023

FibroTest

Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.

Poynard T et al. · Aliment Pharmacol Ther · 2023

FibroTest-T2D NashTest-T2D SteatoTest-T2D Metabolic

Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

Deckmyn O et al. · Biomedicines · 2022

FibroTest Metabolic

External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.

Poynard T et al. · Gastro Hep Adv · 2022

FibroTest LCR1 LCR2 Surveillance-FibroTest +1

Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.

Maisonnasse P et al. · Gastro Hep Adv · 2022

FibroTest COVID

External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.

Poynard T et al. · JHEP Rep · 2021

LCR1 LCR2 HCV

Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.

Poynard T et al. · Aliment Pharmacol Ther · 2021

FibroTest NashTest-2 SteatoTest Metabolic

Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease.

Peta V et al. · Clin Res Hepatol Gastroenterol · 2020

Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.

Poynard T et al. · Eur J Gastroenterol Hepatol · 2020

FibroTest NashTest-2 SteatoTest-2 Metabolic

Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication

Poynard T et al. · PLoS One · 2020

FibroTest COVID

LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.

Poynard T et al. · Aliment Pharmacol Ther · 2019

FibroTest LCR1 LCR2 Alcohol +3

LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication

Poynard T et al. · Aliment Pharmacol Ther · 2019

LCR1 LCR2 Alcohol HBV +4

The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication

Poynard T et al. · Eur J Gastroenterol Hepatol · 2019

NashTest-2 SteatoTest-2 Metabolic

Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.

Munteanu M et al. · Aliment Pharmacol Ther · 2018

FibroTest Alcohol HBV HCV +1

Screening studies of transient elastography and FibroTest in the general population.

Poynard T et al. · Lancet Gastroenterol Hepatol · 2017

FibroTest Other

Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.

Peta V et al. · PLoS One · 2017

ActiTest FibroTest Other